Last reviewed · How we verify
NCT05793957
Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms
NA trial testing Questionnaire Administration in Hematopoietic and Lymphoid System Neoplasm in 50 participants. Completed in 28 September 2023.
28 September 2023
Quick facts
| Lead sponsor | OHSU Knight Cancer Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 50 |
| Start date | 20 April 2023 |
| Primary completion | 28 September 2023 |
| Estimated completion | 28 September 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Questionnaire Administration
- Telephone-Based Intervention
- Virtual Technology Intervention
Conditions studied
- Hematopoietic and Lymphoid System Neoplasm — all drugs for Hematopoietic and Lymphoid System Neoplasm →
- Malignant Breast Neoplasm — all drugs for Malignant Breast Neoplasm →
- Malignant Head and Neck Neoplasm — all drugs for Malignant Head and Neck Neoplasm →
- Malignant Solid Neoplasm — all drugs for Malignant Solid Neoplasm →
Sponsor
OHSU Knight Cancer Institute
Who can join
Adults 18 to 89, any sex, with Hematopoietic and Lymphoid System Neoplasm or Malignant Breast Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial evaluates the use of virtual reality (VR) goggles during chemotherapy infusion to reduce anxiety-related symptoms in patients with head and neck, thoracic, hematologic, and breast cancers. Virtual reality headsets provide the ability for users to explore a simulated, three-dimensional environment with which users can interact. In virtual reality users can play interactive games, enjoy relaxing experiences, and watch immersive videos. The use of VR goggles may help with anxiety management during chemotherapy infusion.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05793957
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionnaire Administration
Trials testing the same drug.
- NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
- NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
- NCT06732388 — Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's E · Phase 2 · not yet recruiting
- NCT05095948 — Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center · not yet recruiting
- NCT07281547 — Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometr · Phase 4 · not yet recruiting
Other recruiting trials for Hematopoietic and Lymphoid System Neoplasm
Currently open trials in the same condition.
- NCT07221409 — Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment · NA · recruiting
- NCT06206863 — Community-Based Physical Activity Intervention for Underserved Cancer Survivors · NA · recruiting
- NCT06059391 — CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Unde · Phase 2 · recruiting
- NCT06169267 — Passive Music Intervention for the Reduction of Anxiety in Patients Undergoing Bone Marrow Aspiration and/or Biopsy · Phase 3 · active not recruiting
- NCT06198010 — A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors · NA · recruiting
Other OHSU Knight Cancer Institute trials
Trials by the same sponsor.
- NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
- NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
- NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
- NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05793957 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
- Last refreshed: 19 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05793957.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing